Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood loss

Abstract

A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 200 mg to 250 mg per oral combination drug formulation.

What is claimed is: 
     
       1. A method for relieving menstrual pain and reducing menstrual blood loss in a female comprising:
 administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 200 mg to 250 mg per the oral combination drug formulation; wherein a total daily dose of the tranexamic acid ranges from 390 mg to 500 mg. 
 
     
     
       2. The method of  claim 1 , wherein the oral combination drug formulation is in a form of any one of: an oral tablet, an oral capsule, and an oral caplet. 
     
     
       3. The method of  claim 2 , wherein the NSAID comprises any one of: ibuprofen, naproxen, diclofenac, ketoprofen, mefenamic acid, and metabolites thereof. 
     
     
       4. The method of  claim 3 , wherein the dose of the NSAID per oral combination drug formulation ranges from 5 mg to 1000 mg. 
     
     
       5. The method of  claim 4 , wherein the dose of the NSAID per oral combination is any one of: from 100 mg to 800 mg of the ibuprofen, from 150 mg to 600 mg of the naproxen, from 5 mg to 50 mg of the diclofenac, from 5 mg to 50 mg of the ketoprofen, and from 50 mg to 500 mg of the mefenamic acid. 
     
     
       6. The method of  claim 1 , wherein the female has a condition that comprises any one of: primary dysmenorrhea, secondary dysmenorrhea, menorrhagia, idiopathic menorrhagia, cyclic heavy menstrual bleeding, dysfunctional uterine bleeding, anemia, menstrual bleeding of less than 80 ml per menstrual cycle, and menstrual bleeding of more than 80 ml per menstrual cycle. 
     
     
       7. The method of  claim 1 , wherein the oral combination drug formulation is administered: from the onset of menstrual bleeding until the resolution of related symptoms; from the onset of menstrual bleeding until the end of the menstrual period. 
     
     
       8. A method for relieving menstrual pain and reducing menstrual blood loss in a female comprising:
 administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of the menstrual blood loss, wherein a total daily dose and a dose per oral combination drug formulation of tranexamic acid is selected based on a contribution of the NSAID to the reduction of menstrual blood loss and wherein the dose of the tranexamic acid per the oral combination drug formulation ranges from 200 mg to 250 mg; wherein a total daily dose of the tranexamic acid ranges from 390 mg to 500 mg. 
 
     
     
       9. The method of  claim 8 , wherein the NSAID has any one of: proven analgesic efficacy and an indication for the treatment of menstrual pain. 
     
     
       10. The method of  claim 8 , wherein the NSAID comprises any one of: ibuprofen, naproxen, diclofenac, ketoprofen, mefenamic acid, and metabolites thereof. 
     
     
       11. The method of  claim 8 , wherein the dose of the tranexamic acid per oral combination drug formulation is any one of: from 200 mg to 225 mg, and from 225 mg to 250 mg. 
     
     
       12. The method of  claim 10 , wherein the oral combination drug formulation comprises 400 mg of the ibuprofen and 250 mg of the tranexamic acid. 
     
     
       13. The method of  claim 10 , wherein the oral combination drug formulation comprises 200 mg of the ibuprofen and 200 mg of the tranexamic acid.